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We have previously shown that inhibition of the MEK
pathway with selumetinib greatly reduced T cell prolifera-
tion induced by allo-DC stimulation with minimal loss in
virus-speciﬁc cytokine production in EBV and CMV-stimu-
lated T cells in vitro, and that selumetinib signiﬁcantly
reduced GVHD and increased survival in a GVHD mouse
model. Thus, MEK inhibitors represent a novel class of
immunosuppressive agents that potentially target GVHD
initiation while sparing beneﬁcial immunity in the allo-SCT
setting. We sought to determine if trametinib, a recently
FDA-approved MEK inhibitor based on clinical responses inFigure 1
Figure 2the melanoma setting, would also demonstrate selective
inhibition of alloreactivity while preserving virus-speciﬁc
immune function. In 6 allo-DC/responder PBMC pairs, we
assessed the dose response of inhibition of proliferation by
trametinib, and found similar dose response patterns to
selumetinib with w50% inhibition of alloreactivity at the 1
mM dose and nearly complete inhibition at 10 mM (Figure 1).
As previously reported with selumetinib, the percentage of
polyfunctional CMV and EBV-stimulated PBMC capable of
producing IL-2, IFN-g, TNF-a or MIP1-b was unchanged by
exposure to MEK inhibition (n¼4, CMV pp65 peptide re-
sponses shown in Figure 2). While the overall fraction of
functional responding cells to virus did not change in
response to MEK inhibition, TNF-a production was reduced
at higher doses of both trametinib and selumetinib. Further
experiments are planned, both in vitro and in animal models,
to conﬁrm the potential utility of this class of drugs to reduce
GVHD while preserving virus-speciﬁc T cell function in the
allo-SCT setting.441
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